ION775 / Ionis - LARVOL DELTA

ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia (ESC 2026) - "Baseline mean (SD) apoC-III and TGs were 13.0 (3.4) mg/dL and 224.0 (69.2) mg/dL, respectively. ION775 was well tolerated, with no serious or severe adverse events and no injection-site reactions. ION775 produced rapid, sustained, dose-dependent reductions in apoC-III and TGs."

Cardiovascular • Dyslipidemia • APOB

Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia. (PubMed, J Clin Lipidol) - "Single-dose ION775 was generally well tolerated and produced rapid, dose-dependent, durable reductions in apoC-III and triglycerides sustained through 12 months, supporting further development as an infrequently dosed therapy for triglyceride-rich lipoprotein disorders."

Clinical • Journal • Dyslipidemia • Hypertriglyceridemia • APOB

A Study to Assess the Safety, Tolerability and Efficacy of ION775 (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Ionis Pharmaceuticals, Inc.

New P2 trial • Dyslipidemia • Hypertriglyceridemia • Severe Hypertriglyceridemia

…Ionis will share positive interim Phase 1 results of ION775, an apoC-III siRNA with the potential for semiannual dosing and Ionis’ first clinical-stage siRNA medicine. (Ionis Pharmaceuticals Press Release) - "ION775 achieved substantial, durable and sustained reductions in apoC-III and fasting triglycerides with favorable safety and tolerability in healthy volunteers with moderately elevated triglycerides. Ionis is on track to initiate a Phase 2 study in 2026."

New P2 trial • P1 data • Severe Hypertriglyceridemia